- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Spyre Therapeutics Inc (SYRE)
Spyre Therapeutics Inc stock price live, this page displays NASDAQ SYRE stock exchange data. View the SYRE premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Spyre Therapeutics Inc real time stock price chart below.
What Is the Spyre Therapeutics Inc Stock Price Today?
The Spyre Therapeutics Inc stock price today is 15.240.
What Is the Stock Symbol for Spyre Therapeutics Inc?
The stock symbol for Spyre Therapeutics Inc is ""SYRE.""
What Stock Exchange Does Spyre Therapeutics Inc Trade On?
Spyre Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Spyre Therapeutics Inc a Good Stock to Buy?
Determining whether Spyre Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SYRE quote. (ISIN: US00773J2024)
What Is the Spyre Therapeutics Inc Stock Price Today?
The Spyre Therapeutics Inc stock price today is 15.240.
What Is the Stock Symbol for Spyre Therapeutics Inc?
The stock symbol for Spyre Therapeutics Inc is ""SYRE.""
What Stock Exchange Does Spyre Therapeutics Inc Trade On?
Spyre Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Spyre Therapeutics Inc a Good Stock to Buy?
Determining whether Spyre Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SYRE quote. (ISIN: US00773J2024)
NASDAQ
Currency in USD
15.240
-0.720(-4.51%)
Closed·
After Hours
15.2400.000(0.00%)
·
Fair Value
An estimate of a Spyre Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.935
15.900
52 wk Range
10.910
40.260
SYRE Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SYRE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Spyre Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.93515.900
52 wk Range
10.91040.260
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SYRE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Spyre Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
54.889
Upside
+260.16%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Form 8K Spyre Therapeutics Inc For: 17 June
- Investing.com
- Form 8K Spyre Therapeutics Inc For: 17 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Spyre Therapeutics Inc Company Profile
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Compare SYRE to Peers and Sector
Metrics to compare | SYRE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSYREPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.7x | −3.1x | −0.5x | |
PEG Ratio | −0.11 | 0.00 | 0.00 | |
Price/Book | 3.1x | 2.2x | 2.6x | |
Price / LTM Sales | - | 9.2x | 3.3x | |
Upside (Analyst Target) | 307.3% | 210.8% | 43.5% | |
Fair Value Upside | Unlock | 11.0% | 6.9% | Unlock |
Analyst Ratings
11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 54.889
(+260.16% Upside)
Earnings
Latest Release
Aug 05, 2025
EPS / Forecast
-0.49 / -0.7538
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Spyre Therapeutics Trade On?
Spyre Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Spyre Therapeutics?
The stock symbol for Spyre Therapeutics is "SYRE."
What Is the Spyre Therapeutics Market Cap?
As of today, Spyre Therapeutics market cap is 909.64M.
What Is Spyre Therapeutics's Earnings Per Share (TTM)?
The Spyre Therapeutics EPS (TTM) is -3.01.
When Is the Next Spyre Therapeutics Earnings Date?
Spyre Therapeutics will release its next earnings report on 05 Nov 2025.
From a Technical Analysis Perspective, Is SYRE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Spyre Therapeutics Stock Split?
Spyre Therapeutics has split 1 times.
How Many Employees Does Spyre Therapeutics Have?
Spyre Therapeutics has 87 employees.
What is the current trading status of Spyre Therapeutics (SYRE)?
As of 07 Aug 2025, Spyre Therapeutics (SYRE) is trading at a price of 15.24, with a previous close of 15.96. The stock has fluctuated within a day range of 14.94 to 15.90, while its 52-week range spans from 10.91 to 40.26.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.